Myelin oligodendrocyte glycoprotein antibody-associated disease

Summary

Myelin oligodendrocyte glycoprotein antibody-associated disease (MONDO:1040024) is a disease and 13 clinical trials. Top therapeutic interventions include rozanolixizumab, satralizumab, and tocilizumab. A subtype of demyelinating disease of central nervous system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myelin oligodendrocyte glycoprotein antibody-associated disease
Mondo ID	MONDO:1040024
UMLS	C5554054
MedGen	1813985
Is cancer (heuristic)	no

Disease family

This is a subtype of demyelinating disease of central nervous system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › demyelinating disease › demyelinating disease of central nervous system › myelin oligodendrocyte glycoprotein antibody-associated disease

Related subtypes (1): multiple sclerosis

Subtypes (4): neuromyelitis optica spectrum disorder with anti-MOG antibodies, acute transverse myelitis with anti-MOG antibodies, isolated optic neuritis with anti-MOG antibodies, acute disseminated encephalomyelitis with anti-MOG antibodies

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE3	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05063162	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
NCT05271409	PHASE3	RECRUITING	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT06452537	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT04561557	EARLY_PHASE1	RECRUITING	Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
NCT05017142	Not specified	RECRUITING	Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
NCT05204459	Not specified	RECRUITING	MS-ResearchBiomarkerS
NCT06280755	Not specified	RECRUITING	Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
NCT06474520	Not specified	RECRUITING	Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
NCT06541626	Not specified	RECRUITING	Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
NCT07202494	Not specified	RECRUITING	Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
NCT07333196	Not specified	NOT_YET_RECRUITING	Tongji NADs Cohort
NCT05605951	Not specified	UNKNOWN	Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
NCT06443333	Not specified	UNKNOWN	National, Multicentric Registry Study on Neuroimmunological Diseases in China

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ROZANOLIXIZUMAB	4	1
SATRALIZUMAB	4	1
TOCILIZUMAB	4	1